Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company focused on developing novel therapies for psychiatric disorders, has recently received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application 17/954,864. This patent, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,” is expected to be formally issued within the next 90 days and will significantly enhance the protection of Silo’s lead asset, SPC-15, an intranasal treatment aimed at post-traumatic stress disorder (PTSD).
The newly allowed patent expands upon Silo’s existing U.S. Patent 11,491,120, which was granted in February 2023. This strategic move not only broadens the company’s intellectual property portfolio but also reinforces its market position in a competitive landscape. Eric Weisblum, CEO of Silo Pharma, expressed optimism about the patent’s approval, stating, “We are pleased to kick off 2025 with this expected addition to our intellectual property portfolio.”
SPC-15 is a serotonin 5-HT4 receptor agonist designed to address stress-induced disorders such as PTSD and anxiety. Its unique intranasal delivery system may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, potentially expediting its approval process. The company is currently collaborating with Columbia University on preclinical studies to further advance this promising treatment.
The exclusive licensing agreement with Columbia University provides Silo with extensive patents and pending applications related to SPC-15 technology. This partnership not only adds credibility but also enhances Silo’s capabilities in developing and commercializing innovative therapies globally.
The significance of this patent extends beyond mere legal protection; it positions Silo Pharma to target a substantial yet underserved demographic, women suffering from PTSD. The gender-specific claims included in the patent could allow the company to carve out a niche in a market that has historically been overlooked.
As the global PTSD therapeutics market continues to expand, projected to reach significant figures in the coming years, Silo Pharma’s focus on developing effective treatments aligns well with current healthcare needs. The company’s commitment to addressing underserved conditions is evident through its diverse pipeline, which includes other investigational drugs such as SP-26, a time-release ketamine implant for chronic pain relief.
In addition to its advancements in PTSD treatment, Silo is also exploring the potential of SPC-15 in treating other stress-related disorders and conditions like eating disorders and anorexia. Recent preclinical studies suggest that combining SPC-15 with an NMDA receptor antagonist may enhance therapeutic efficacy for major depressive disorder and other severe stress-related conditions.
Silo Pharma’s proactive approach towards clinical trials reflects its dedication to innovation in biopharmaceuticals. The company is gearing up for an Investigational New Drug (IND) application submission to the FDA in 2025, which would pave the way for Phase 1 clinical trials targeting PTSD.
